Tri-Blend is a 30 mg vial of 10 mg each BPC-157, TB-500 and KPV, sold as a copper-free repair stack.
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
Tri-Blend is 3 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
BPC-15710 mg per vial
TB-500 / TB-410 mg per vial
KPV10 mg per vial
What published studies and recent community write-ups report about amounts, timing and course length. 1 preclinical and 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical1 row | |||||
| Related two-peptide combination in rats: BPC-157 plus TB-500 after Achilles tendon repair (no KPV arm; not the product)32 male Sprague-Dawley rats, 8 per group, after Achilles tendon transection and repair | BPC-157 10 mcg/kg per day; TB-500 60 mcg/kg per day; both together in the combination group | Once daily | Intraperitoneal | 4 weeks after surgeryNot applicable | Joint Diseases and Related Surgery (PubMed)2026 |
| TB-500 alone significantly raised load to failure and improved tendon histology, BPC-157 alone improved scores without reaching significance, and the combination improved one histology score but added nothing over either agent alone; the authors suggest the two converge on shared pathways. It is the only published animal work found on any pair of this vial's peptides and it does not support the synergy the blend is sold on. | |||||
| Community-reported2 rows | |||||
| Telehealth compounded 1:1:1 vial (15 mg of each in 5 mL), a related presentation rather than the 10/10/10 research vial | 20 units (0.2 mL) delivering 0.6 mg each of BPC-157, TB-500 and KPV at 3 mg/mL of each | Once daily, Monday to Friday; a common pattern is daily for the first 2 weeks, then 2-3 doses a week | Subcutaneous into abdominal fat with a 31-gauge 8 mm insulin syringe, rotating sites | 4-12 weeks, set by the prescriberWeekends off; the end of the course is a reassessment point to pause, repeat or stop | Community resource2026 |
| One telehealth prescriber writes the prescription and a 503A pharmacy ships the vial pre-reconstituted with a 90-day beyond-use date, so there is nothing to mix. The page calls this the no-copper triple for people already injecting GHK-Cu, with copper sensitivity or a copper-handling disorder, or who prefer copper kept topical, and it states that the three-peptide combination has never been tested as a single formula in a human trial and that no study has compared it with the four-peptide KLOW. Telehealth vendor claims, and a 15/15/15 vial rather than the 10/10/10 one in the catalog, though the ratio is the same. | |||||
| Community dosage guide for the BPC-157 / TB-500 / KPV family (Coremend, Tri-Heal Max) | Component reference ranges: BPC-157 250-500 mcg once or twice daily, KPV 200-500 mcg daily, TB-500 2-2.5 mg twice weekly in a loading phase then once weekly; the page's own schedule card lists 250 mcg per injection | Daily on the schedule card; component-specific in the FAQ | Subcutaneous, abdomen or thigh, sometimes near the injury | 6 weeks on the schedule card; 6-8 weeks, sometimes 12 for chronic problems, in the FAQ2-4 weeks off before another cycle | Community resource2026 |
| One community guide's page treats 25/10/10 (45 mg) as the common Coremend ratio and says some vendors sell an equal 10/10/10 version, so its figures have to be re-read for the catalog vial. It describes 2-3 mL of bacteriostatic water, refrigeration and use within about 30 days, says the dosing comes from vendor and enthusiast guides rather than clinical studies, and lists injection-site redness, flushing, nausea, fatigue and headache as the side effects users report. The component ranges cannot all be met from one 1:1:1 vial: a draw that delivers 2 mg of TB-500 also delivers 2 mg each of BPC-157 and KPV. | |||||
The 30 mg vial is lyophilised powder that the vendor says to reconstitute with bacteriostatic water, refrigerate, use within 30 days and never freeze; its lot report describes a white powder, so unlike the copper blends there is no colour to read. Other guides describe 2-3 mL of water for this family of vials.
One community guide's stage table attributes the earliest reports to KPV's anti-inflammatory action and places accelerating repair in weeks 1-2. The compounded protocol runs daily, weekdays only, through this period.
The same table places collagen remodelling in weeks 2-4 and advanced regeneration in weeks 4-8, with week 8 as the point to assess cycling off; the FAQ gives 6-8 weeks, sometimes 12, followed by a 2-4 week break. The compounded version tapers to 2-3 doses a week after the first fortnight and ends at a prescriber review between weeks 4 and 12.
No trial has followed anyone on this blend. In the one animal study of BPC-157 plus TB-500 together, four weeks of daily injections improved tendon histology but no more than either peptide alone, and the timelines above are what guides publish rather than observed courses.
Plus 7 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
What sources report for each peptide on its own. In Tri-Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
Tri-Blend is a 30 mg vial of 10 mg each BPC-157, TB-500 and KPV, sold as a copper-free repair stack. The name is a vendor label: one vendor lists this 10/10/10 vial as Tri-Blend, another sells the same composition as Wolverine Plus and a third as AEGIS, while the Coremend or Tri-Heal name usually means a heavier 25/10/10 TB-500 version; all of them market it as the BPC-157 and TB-500 Wolverine pairing with KPV added for inflammation, or as KLOW without GHK-Cu. No study has tested the three together; the closest evidence is a 2026 rat study in which BPC-157 plus TB-500 added nothing over either alone and a 2021 uncontrolled knee-injection chart review in which 4 patients received BPC-157 with thymosin beta-4, so the rows below are vendor and community accounts.
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
Structured review queued
No evidence level is assigned until references and study models are reviewed.
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Each number is the vial amount for that component. It is not a per-draw amount.
5 curated references, each with its journal, year and study model, plus 7 community resources reported but not linked.